PCM
RPRX

Prelude Capital Management’s Repros Therapeutics Inc. RPRX Stock Holding History

Prelude Capital Management’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2013
Q4 		– Sell
-500
Closed -$13K – 2297
2013
Q3 		$13K Buy
+500
New +$10.7K ﹤0.01% 1257

Other funds holding RPRX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
GAI
General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return
AIA
Allegis Investment Advisors Idaho Falls, Idaho $326M AUM 10.36% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
California Public Employees Retirement System
California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return
Jacobs Levy Equity Management
Jacobs Levy Equity Management Florham Park, New Jersey $23.8B AUM 25.4% 1-Year Est. Return

Prelude Capital Management's RPRX Position: Q1 2017 in Review

Prelude Capital Management sold out of Repros Therapeutics Inc. (RPRX) in Q1 2017, closing a stake of 3,700 shares — an estimated $5K sold.

Prelude Capital Management first reported a position in RPRX in Q2 2013 and held it in 5 quarters. The position peaked at $86K in Q3 2013. 33 funds tracked by Wall St. Rank hold RPRX as of Q1 2017.

  • Prelude Capital Management reported no remaining Repros Therapeutics Inc. position as of Q1 2017 after selling out during the quarter.
  • Prelude Capital Management sold 3,700 Repros Therapeutics Inc. shares in Q1 2017, an estimated $5K.
  • Prelude Capital Management first reported a position in Repros Therapeutics Inc. in Q2 2013 and held it in 5 quarters.
  • Prelude Capital Management's Repros Therapeutics Inc. position peaked at $86K in Q3 2013.
  • 33 funds tracked by Wall St. Rank held Repros Therapeutics Inc. as of Q1 2017.

Based on Prelude Capital Management's 13F filing for Q1 2017, filed 15 May 2017.